$60.45
2.31 (-3.68%)
Last updated: Apr 16, 2026 00:41
Fundamentals Overview
Vaxcyte, Inc. is near the high of its 52-week range with moderate valuation, trending downward today.
Valuation moderate
Risk (Beta)
1.39 — higher vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
3M vs S&P 500: +31.2% · 3M vs Healthcare sector: +38%
Pressures (Sell):
Beta 1.39 (elevated)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C-. Current institutional positions: Buy: 28, Outperform: 2.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-0.57; current price is $60.45. That’s a -100.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 3.06 |
| P/S (TTM) | N/A |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 7.91 |
| Quick Ratio (TTM) | 7.91 |
| Cash Ratio (TTM) | 0.85 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 0% |
| Gross margin (TTM) | 0% |
| Operating margin (TTM) | 0% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for PCVX.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| BTIG | maintain | Buy | Buy | 2026-02-26 |
| Guggenheim | maintain | Buy | Buy | 2026-02-02 |
| BTIG | maintain | Buy | Buy | 2025-11-10 |
| BTIG | maintain | Buy | Buy | 2025-10-16 |
| Needham | maintain | Buy | Buy | 2025-04-08 |
| B of A Securities | maintain | Buy | Buy | 2025-04-01 |
| Needham | maintain | Buy | Buy | 2025-04-01 |
| Goldman Sachs | maintain | Buy | Buy | 2025-04-01 |
| Guggenheim | maintain | Buy | Buy | 2025-03-12 |
| Guggenheim | maintain | Buy | Buy | 2025-02-26 |
| Needham | maintain | Buy | Buy | 2025-02-26 |
| BTIG | maintain | Buy | Buy | 2025-02-24 |
| Needham | maintain | Buy | Buy | 2025-02-11 |
| BTIG | maintain | Buy | Buy | 2024-12-24 |
| Needham | maintain | Buy | Buy | 2024-11-06 |
| Mizuho | maintain | Outperform | Outperform | 2024-09-10 |
| B of A Securities | maintain | Buy | Buy | 2024-09-04 |
| Needham | maintain | Buy | Buy | 2024-09-03 |
| BTIG | maintain | Buy | Buy | 2024-09-03 |
| Leerink Partners | maintain | Outperform | Outperform | 2024-09-03 |
| Jefferies | maintain | Buy | Buy | 2024-09-03 |
| BTIG | maintain | Buy | Buy | 2024-08-07 |
| Needham | maintain | Buy | Buy | 2024-08-07 |
| Needham | maintain | Buy | Buy | 2024-06-28 |
| Needham | maintain | Buy | Buy | 2024-05-09 |
| Needham | maintain | Buy | Buy | 2024-04-10 |
| Mizuho | maintain | Buy | Buy | 2024-03-12 |
| Needham | maintain | Buy | Buy | 2024-02-28 |
| B of A Securities | maintain | Buy | Buy | 2024-01-02 |
| Needham | maintain | Buy | Buy | 2023-11-07 |